{"nctId":"NCT05707351","briefTitle":"A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A","startDateStruct":{"date":"2023-03-27","type":"ACTUAL"},"conditions":["Hemophilia A"],"count":37,"armGroups":[{"label":"Adynovate 45Â±5 IU/kg","type":"EXPERIMENTAL","interventionNames":["Biological: Adynovate"]}],"interventions":[{"name":"Adynovate","otherNames":["Antihemophilic Factor (recombinant) PEGylated, Rurioctocog Alfa Pegol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Participant and/or legally authorized representative must voluntarily sign a written informed consent form (ICF) after all relevant aspects of the study have been explained and discussed with the Participant. For the participants less than (\\<) 18 years old, participants will give assent AND their parents/legally authorized representative should sign the ICF accordingly.\n2. Participant and/or legally authorized representative understands and is willing and able to comply with all requirements of the study protocol.\n3. Participant should be ethnic Chinese.\n4. Participant is 12 to 65 years of age at screening and male.\n5. Participant has severe hemophilia A (FVIII clotting activity \\<1 percent \\[%\\]) as confirmed by the central laboratory at screening after a washout period of at least 72 to 96 hours.\n6. The last on-demand or prophylactic treatment received is within 3 months before screening.\n7. Participant has documented previous treatment with plasma-derived FVIII concentrates or recombinant FVIII for greater than (\\>) 150 EDs.\n8. Participant is human immunodeficiency virus (HIV)-negative, or HIV-positive with stable disease and CD4+ count greater than or equal to (\\>=) 200 cells per cubic millimeter (/mm\\^3).\n9. Participant is hepatitis C virus (HCV) negative by antibody testing (if positive, additional polymerase chain reaction testing will be performed to confirm), as confirmed at screening; or HCV-positive with chronic stable hepatitis, as assessed by the investigator.\n\nExclusion Criteria:\n\n1. Participant has detectable FVIII inhibitory antibodies (\\>=0.6 Bethesda units \\[BU\\] per milliliter \\[/mL\\] using the Nijmegen modification of the Bethesda assay) as confirmed by the central laboratory at screening.\n2. Participant has a confirmed history of FVIII inhibitory antibodies (\\>=0.6 BU using the Nijmegen modification of the Bethesda assay or \\>=0.6 BU using the Bethesda assay) at any time prior to screening.\n3. Participant has a known hypersensitivity to Adynovate or ADVATE or any of the components of the study drugs, such as mouse or hamster proteins, or other FVIII products.\n4. Participant has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (example, qualitative platelet defect or von Willebrand's disease).\n5. Participant has severe hepatic dysfunction (example, \\>=5 times the upper limit of normal \\[ULN\\] for alanine aminotransferase \\[ALT\\] or aspartate aminotransferase \\[AST\\], a recent or persistent international normalized ratio \\[INR\\] \\>1.5, as confirmed by the local laboratory at screening).\n6. Participant has severe renal impairment (serum creatinine \\>1.5 times the ULN) as confirmed by the local laboratory at screening.\n7. Participant is planned or likely to undergo major surgery during the study period.\n8. Participant has current or recent (\\<30 days) use of other PEGylated drugs before study participation or scheduled use of such drugs during study participation.\n9. Participant has received emicizumab therapy within 6 months of screening.\n10. Participant is currently receiving, or scheduled to receive during the study, an immunomodulating drug (example, systemic corticosteroid agent at a dose equivalent to hydrocortisone \\>10 milligram per day \\[mg/day\\], or alpha-interferon) other than antiretroviral chemotherapy.\n11. Participant has participated in another clinical study involving the use of an investigational product (IP) other than Adynovate or an investigational device within 30 days before the screening visit or is scheduled to participate in another clinical study involving an IP or investigational device during this study.\n12. Participant has a medical, psychiatric, or cognitive illness or recreational drug/alcohol use that, in the opinion of the investigator, would affect participant safety or compliance.\n13. Participant, in the opinion of the investigator, is unable or unwilling to comply with the study protocol.","healthyVolunteers":false,"sex":"MALE","minimumAge":"12 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Annualized Bleeding Rates (ABR)","description":"Total ABR was defined as the number of treated and non-treated bleeding episodes (BEs) that occurred during the treatment period, calculated as, ABR= number of unique bleeds during treatment period/(length of treatment period \\[days\\]/365.25). Total ABR for all BEs, spontaneous or traumatic, recorded in the participant's electronic diary and/or recorded in the physician/nurse/study site notes were reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"13.61"}]}]}]},{"type":"SECONDARY","title":"ABR Based on Bleeding Site","description":"ABR= number of unique bleeds during treatment period/(length of treatment period \\[days\\]/365.25). ABR for BEs based on bleeding site: joint or non-joint, recorded in the participant's electronic diary and/or recorded in the physician/nurse/study site notes were reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"8.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"5.48"}]}]}]},{"type":"SECONDARY","title":"ABR Based on Bleeding Cause","description":"ABR= number of unique bleeds during treatment period/(length of treatment period \\[days\\]/365.25). ABR for BEs based on bleeding cause: spontaneous/unknown or injury, recorded in the participant's electronic diary and/or recorded in the physician/nurse/study site notes were reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"13.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.99"}]}]}]},{"type":"SECONDARY","title":"Number of Adynovate Infusions Per Week During the Prophylactic Treatment Period","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.003","spread":"0.0563"}]}]}]},{"type":"SECONDARY","title":"Number of Adynovate Infusions Per Month During the Prophylactic Treatment Period","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.711","spread":"0.2447"}]}]}]},{"type":"SECONDARY","title":"Weight-adjusted Consumption of Adynovate Per Week During the Prophylactic Treatment Period","description":"Weight-adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.637","spread":"3.6807"}]}]}]},{"type":"SECONDARY","title":"Weight-adjusted Consumption of Adynovate Per Month During the Prophylactic Treatment Period","description":"Weight-adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"389.760","spread":"16.0045"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Zero Bleeding Episodes During the Study","description":"Percentages were rounded off to the nearest single decimal place.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Time Interval Between Bleeding Episodes (BEs)","description":"Average time interval between bleeding episodes (days)= Length of treatment period (days)/ Number of unique bleeds during treatment period. Average time interval was computed for participants with more than 1 unique BEs.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.869","spread":"30.9437"}]}]}]},{"type":"SECONDARY","title":"Number of Bleeding Events in Each Category of Hemostatic Efficacy Rating at Resolution of Breakthrough Bleeding Episode","description":"Hemostatic efficacy for treatment of BEs was rated on 4-point Likert scale as: excellent=full relief of pain and cessation of objective signs of bleeding after a single infusion, no additional infusion is required for the control of bleeding and administration of further infusion to maintain hemostasis would not affect the scoring; good=definite pain relief and/or improvement in signs of bleeding after a single infusion, possibly requires more than 2 infusions for complete resolution and administration of further infusion to maintain hemostasis would not affect the scoring; fair=probable and/or slight relief of pain and slight improvement in signs of bleeding after a single infusion, required multiple infusions for complete resolution; none=no improvement of signs or symptoms or conditions worsen. Missing indicates the number of unique bleeding episodes without any overall hemostatic efficacy rating at resolution of breakthrough bleeding episode.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Adynovate Infusions Per Bleeding Episode","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.839","spread":"2.9337"}]}]}]},{"type":"SECONDARY","title":"Weight-adjusted Consumption of Adynovate Per Bleeding Episode","description":"Weight-adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.766","spread":"81.7538"}]}]}]},{"type":"SECONDARY","title":"Number of Minor Surgeries With Hemostatic Efficacy Based on Global Hemostatic Efficacy Assessment (GHEA) Score as Assessed by the Operating Surgeon/Investigator","description":"GHEA score consisted of 3 individual rating scales: (1) Intra-operative Efficacy Assessment Scale, (2) Post-operative Efficacy Assessment Scale, and (3) Peri-operative Efficacy Assessment Scale. Each rating scale is based on 4 points scale ranging from: 3 (Excellent), 2 (Good), 1 (Fair), and 0 (None). The scores of 3 individual ratings scales were added together to form a GHEA score. Total score ranged from 0 to 9, where scores evaluate as: excellent (7 to 9), good (5 to 7), fair (3 to 4), and none (0 to 2). For a GHEA score of 7 to be rated \"excellent\" no individual assessment scores could be less than (\\<) 2 and at least 1 assessment score had to be equal to (=) 3; otherwise a score of 7 was rated \"good\".","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Volume of Actual and Predicted Intra-operative and Post-operative Blood Loss After the Surgery as Assessed by the Operating Surgeon/Investigator","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of Participants Who Required Perioperative Transfusion of Blood, Red Blood Cells, Platelets, and Other Blood Products","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Daily Intra-Operative and Post-Operative Weight-Adjusted Consumption Dose of Adynovate","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (Serious TEAEs)","description":"An adverse event (AE): any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to medicinal product. TEAE: any AE either reported for the first time or worsening of a pre-existing event after first dose of study drug and within 30 days of the last administration of study drug. Serious TEAEs: any untoward medical occurrence that: 1) results in death, 2) is life-threatening, 3) requires inpatient hospitalization or prolongation of existing hospitalization, 4) results in persistent or significant disability/incapacity, 5) leads to a congenital anomaly/birth defect in the offspring of the participant or 6) is a medically important.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Confirmed Inhibitory Antibodies to Factor VIII (FVIII), Binding Immunoglobulin G (IgG) and Immunoglobulin M (IgM) Antibodies to Adynovate and Chinese Hamster Ovary (CHO) Protein","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"FVIII Activity Level in Plasma Assessed by a 1-stage Clotting Assay","description":"As per planned analysis, data for this outcome measure was collected and reported for initial pharmacokinetic (PK) assessment and second PK assessment. The initial PK assessment was performed prior to the baseline visit at Day -1. The second PK assessment was performed during the Week 20 visit. FVIII activity level reported was corrected for pre-infusion measurement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112.02","spread":"26.739"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106.67","spread":"22.066"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.64","spread":"32.185"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.67","spread":"21.186"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.87","spread":"16.929"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.96","spread":"14.378"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.24","spread":"11.573"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.60","spread":"7.616"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.17","spread":"3.876"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.06","spread":"2.040"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109.75","spread":"18.192"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109.51","spread":"20.705"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.82","spread":"20.196"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.41","spread":"9.587"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.57","spread":"15.750"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.31","spread":"14.766"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.53","spread":"11.918"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.13","spread":"8.275"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.20","spread":"4.754"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.25","spread":"2.811"}]}]}]},{"type":"SECONDARY","title":"Incremental Recovery Over Time During Adynovate Prophylactic Treatment","description":"Incremental recovery (IR) was calculated as IR (international units per deciliter)/(international units per kilogram \\[(IU/dL)/(IU/kg)\\] = \\[PostFVIII (IU/dL)-PreFVIII (IU/dL)\\]/Weight Adjusted Dose (IU/kg).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4777","spread":"0.67876"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5147","spread":"0.64379"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4083","spread":"0.50714"}]}]}]},{"type":"SECONDARY","title":"Pre-dose Level of FVIII Activity in Plasma","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.232"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.28","spread":"4.999"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.91","spread":"2.802"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.61","spread":"3.994"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.06","spread":"16.365"}]}]}]},{"type":"SECONDARY","title":"Pre-dose Level of FVIII Antigen in Plasma","description":"IU/mL stands for international units per milliliter.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0276","spread":"0.06577"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0782","spread":"0.07888"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0689","spread":"0.04518"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0649","spread":"0.04286"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0856","spread":"0.05404"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1011","spread":"0.11326"}]}]}]},{"type":"SECONDARY","title":"Pre-dose Level of Von Willebrand Factor (VWF) Antigen in Plasma","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.69","spread":"35.967"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.46","spread":"30.811"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.99","spread":"34.216"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.57","spread":"30.024"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.26","spread":"34.240"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.26","spread":"31.714"}]}]}]},{"type":"SECONDARY","title":"Clearance (CL) for FVIII Activity Following an Initial Single Dose and Steady-state Dose of Adynovate","description":"Clearance reported was calculated based on pre-infusion corrected concentration data. As per planned analysis, data for this outcome measure was collected and reported for initial PK assessment and second PK assessment. The initial PK assessment was performed prior to the baseline visit at Day -1. The second PK assessment was performed during the Week 20 visit. \\[(dL/h)/kg\\] stands for deciliters per hour per kilogram.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0206","spread":"0.00629"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0192","spread":"0.00594"}]}]}]},{"type":"SECONDARY","title":"Volume of Distribution for FVIII Activity Following an Initial Single Dose and Steady-state Dose of Adynovate","description":"Volume of distribution was calculated based on pre-infusion corrected concentration data. As per planned analysis, data for this outcome measure was collected and reported for initial PK assessment and second PK assessment. The initial PK assessment was performed prior to the baseline visit at Day -1. The second PK assessment was performed during the Week 20 visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.458","spread":"0.107"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.480","spread":"0.0953"}]}]}]},{"type":"SECONDARY","title":"Area Under the Concentration Versus Time Curve From 0 to 96 Hours (AUC0-96) for FVIII Activity Following an Initial Single Dose and Steady-state Dose of Adynovate","description":"AUC0-96 was calculated based on pre-infusion corrected concentration data. As per planned analysis, data for this outcome measure was collected and reported for initial PK assessment and second PK assessment. The initial PK assessment was performed prior to the baseline visit at Day -1. The second PK assessment was performed during the Week 20 visit. h\\*IU/dL stands for hour\\*international units per deciliter.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2348","spread":"737"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2582","spread":"736"}]}]}]},{"type":"SECONDARY","title":"Maximum Concentration (Cmax) for FVIII Activity Following an Initial Single Dose and Steady-state Dose of Adynovate","description":"Cmax was calculated based on pre-infusion corrected concentration data. As per planned analysis, data for this outcome measure was collected and reported for initial PK assessment and second PK assessment. The initial PK assessment was performed prior to the baseline visit at Day -1. The second PK assessment was performed during the Week 20 visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":"26.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":"20.0"}]}]}]},{"type":"SECONDARY","title":"Pre-dose Concentration (Cpredose) for FVIII Activity Following an Initial Single Dose and Steady-state Dose of Adynovate","description":"Cpredose was calculated based on pre-infusion corrected concentration data. As per planned analysis, data for this outcome measure was collected and reported for initial PK assessment and second PK assessment. The initial PK assessment was performed prior to the baseline visit at Day -1. The second PK assessment was performed during the Week 20 visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Terminal Phase Elimination Half-life (T1/2) for FVIII Activity Following an Initial Single Dose and Steady-state Dose of Adynovate","description":"T1/2 was calculated based on pre-infusion corrected concentration data. As per planned analysis, data for this outcome measure was collected and reported for initial PK assessment and second PK assessment. The initial PK assessment was performed prior to the baseline visit at Day -1. The second PK assessment was performed during the Week 20 visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":"3.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":"4.61"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":37},"commonTop":["Arthralgia","Diarrhoea","Alanine aminotransferase increased","Aspartate aminotransferase increased","Hyperlipidaemia"]}}}